Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML

We conducted an open-label phase 1 study exploring the feasibility, safety, and biologic activity of epigenetic priming with decitabine before standard induction chemotherapy in patients with less-than-favorable risk of acute myelogenous leukemia (AML). We directly compared the clinical and DNA-hypo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Scandura, Joseph M., Roboz, Gail J., Moh, Michelle, Morawa, Ewelina, Brenet, Fabienne, Bose, J. Robi, Villegas, Luis, Gergis, Usama S., Mayer, Sebastian A., Ippoliti, Cindy M., Curcio, Tania J., Ritchie, Ellen K., Feldman, Eric J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2011
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3156041/
https://ncbi.nlm.nih.gov/pubmed/21613261
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-11-320093
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados